Tag Archives: Cardiovascular

  Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular disease Pacibekitug is a promising targeted therapy with the potential to reduce systemic inflammation—an independent and significant driver of cardiovascular risk—addressing a critical unmet need in ASCVD treatment Offer price of USD 48 per share valuing the company at approximately …

Share on PinterestA decline in physical activity may signal future heart disease years before symptoms begin, according to new research. Thomas Barwick/Getty Images Several lifestyle changes can help lower the risk for heart disease, including being physically active. A new study found that adults who developed heart disease later in life experienced a decline in their physical activity about 12 …

I’ll start this article with a strong caveat — I’m not a personal trainer or a walking coach, I’m a fitness editor and enthusiast, who reviews gear and tests new workouts for a living. Like the rest of the fitness world, I’ve recently been swept up in the Japanese walking method hype, and it’s changed my walking workouts for good, …

HomeCardiovascular Diseases Over a century of progress in surgery, drugs, prevention, and emergency response has driven down death rates from heart disease and stroke. For much of history, heart disease was a mystery. Middle-aged adults often collapsed without warning, and doctors usually blamed “dropsy”, “apoplexy”, or simply “old age.”1 In 1945 — at just 63 years old — President Franklin …

Lilly’s Mounjaro (tirzepatide), a GIP/GLP-1 dual agonist, demonstrated cardiovascular protection in landmark head-to-head trial, reinforcing its benefit in patients with type 2 diabetes and heart disease  Eli Lilly and Company Eli Lilly’s Mounjaro shows heart health benefits in head-to-head trial with older diabetes drug Trulicity  CNBC Eli Lilly’s diabetes drug Mounjaro matches heart benefit of older treatment  statnews.com Eli Lilly Weight-Loss Drug Mounjaro …

TOPLINE: Moderate- to vigorous-intensity physical activity (MVPA) begins declining approximately 12 years before the onset of cardiovascular disease (CVD), with steeper drops 2 years before its onset. Black women consistently showed the lowest levels of MVPA and were at more than four times higher risk for low MVPA after a cardiovascular event than other groups. METHODOLOGY: Researchers analyzed data from …